Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000824788 | SCV000065526 | pathogenic | Rare genetic deafness | 2011-09-17 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000041830 | SCV000487464 | likely pathogenic | Usher syndrome type 2A | 2015-12-16 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000411413 | SCV000487465 | likely pathogenic | Retinitis pigmentosa 39 | 2015-12-16 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV001073532 | SCV001239079 | likely pathogenic | Retinal dystrophy | 2019-05-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001213213 | SCV001384834 | pathogenic | not provided | 2025-01-23 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Cys1186Trpfs*51) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is present in population databases (rs397518014, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 20613545, 27318125). ClinVar contains an entry for this variant (Variation ID: 48504). For these reasons, this variant has been classified as Pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000041830 | SCV003761493 | pathogenic | Usher syndrome type 2A | 2023-01-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000411413 | SCV004182330 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000041830 | SCV004182331 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000411413 | SCV004200680 | pathogenic | Retinitis pigmentosa 39 | 2023-06-12 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001073532 | SCV005068568 | pathogenic | Retinal dystrophy | 2021-01-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005007962 | SCV005641286 | likely pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-05-03 | criteria provided, single submitter | clinical testing |